[go: up one dir, main page]

RU97113435A - METHOD FOR TREATMENT OF DRUG ADDICTION, AND ALSO PATIENTS WITH DEPENDENCE SYMPTOMS, OR INDEPENDENCE, OR ADDICTION TO MEDICINES OF THE BENZODIAZEPINE GROUP - Google Patents

METHOD FOR TREATMENT OF DRUG ADDICTION, AND ALSO PATIENTS WITH DEPENDENCE SYMPTOMS, OR INDEPENDENCE, OR ADDICTION TO MEDICINES OF THE BENZODIAZEPINE GROUP

Info

Publication number
RU97113435A
RU97113435A RU97113435/14A RU97113435A RU97113435A RU 97113435 A RU97113435 A RU 97113435A RU 97113435/14 A RU97113435/14 A RU 97113435/14A RU 97113435 A RU97113435 A RU 97113435A RU 97113435 A RU97113435 A RU 97113435A
Authority
RU
Russia
Prior art keywords
drug
melatonin
addiction
drugs
group
Prior art date
Application number
RU97113435/14A
Other languages
Russian (ru)
Other versions
RU2182001C2 (en
Inventor
Нава Зисапел
Original Assignee
Неурим Фармасеутикалс (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Неурим Фармасеутикалс (1991) Лтд. filed Critical Неурим Фармасеутикалс (1991) Лтд.
Publication of RU97113435A publication Critical patent/RU97113435A/en
Application granted granted Critical
Publication of RU2182001C2 publication Critical patent/RU2182001C2/en

Links

Claims (8)

1. Способ лечения наркомании, а также больных с симптомами зависимости, или невосприимчивости, или привыкания к лекарствам группы бензодиазепинов с использованием мелотонина для изготовления лечебных лекарственных препаратов, отличающийся тем, что лечебный лекарственный препарат содержит по крайней мере один растворитель, носитель или адьювант и который принимают перорально, или ректально, или парентерально, или трансдермально.1. A method of treating drug addiction, as well as patients with symptoms of dependence, or immunity, or addiction to drugs of the benzodiazepine group using melotonin for the manufacture of therapeutic drugs, characterized in that the therapeutic drug contains at least one solvent, carrier or adjuvant and which taken orally, or rectally, or parenterally, or transdermally. 2. Способ по п. 1, отличающийся тем, что лечебный лекарственный препарат принимают в виде разовой дозы приема, причем каждая доза содержит мелатонин, количество которого лежит в пределах 0,0025 -100 мг. 2. The method according to p. 1, characterized in that the therapeutic drug is taken as a single dose, and each dose contains melatonin, the amount of which lies in the range of 0.0025-100 mg. 3. Способ по пп. 1 и 2, отличающийся тем, что лекарственный препарат представляет препарат с контролируемым выделением, причем мелатонин выделяется с заданной контролируемой скоростью. 3. The method according to PP. 1 and 2, characterized in that the drug is a drug with controlled release, and melatonin is released at a given controlled speed. 4. Способ по пп. 1-3, отличающийся тем, что лекарственный препарат содержит по крайней мере один модификатор мелатонинового рецептора и/или один модификатор характеристики мелатонина. 4. The method according to PP. 1-3, characterized in that the drug contains at least one modifier of the melatonin receptor and / or one modifier of the characteristics of melatonin. 5. Способ по пп. 1-4, отличающийся тем, что лекарственный препарат содержит по крайней мере один активный ингредиент, в качестве которого используют лекарство группы бензодиазепинов. 5. The method according to PP. 1-4, characterized in that the drug contains at least one active ingredient, which is used as a drug of the benzodiazepine group. 6. Способ по пп. 1-5, отличающийся тем, что лекарство группы бензодеазепинов содержит по крайней мере одно из лекарств из ряда: альпрозалам, или хлордиазепоксид, или хлоразепат, или диазепам, или флунитразепам, или флуразепам, или халазепам, или лоразепам, или оксазепам, или праземам, или темазепам, или триазолам. 6. The method according to PP. 1-5, characterized in that the medicine of the benzodeazepine group contains at least one of a series of drugs: alprozalam, or chlordiazepoxide, or chlorazepate, or diazepam, or flunitrazepam, or flurazepam, or chalazepam, or lorazepam, or oxazepam, or praseme, or temazepam, or triazolam. 7. Способ по пп. 1-6, отличающийся тем, что мелатонин принимают отдельно, либо совместно с одним или более лекарствами группы бензодиазепинов, при этом эффективная ежедневная доза должна находиться в пределах 0,01-100 мг. 7. The method according to PP. 1-6, characterized in that melatonin is taken separately, or together with one or more drugs of the benzodiazepine group, while the effective daily dose should be in the range of 0.01-100 mg. 8. Способ по пп. 1-7, отличающийся тем, что качестве модификатора рецептора мелатонина используют оксазепам, а в качестве модификаторов характеристики мелотанина используют бензодиазепины, бета-блокаторы, или ингибиторы поглощения серотонина. 8. The method according to PP. 1-7, characterized in that oxazepam is used as a melatonin receptor modifier, and benzodiazepines, beta-blockers, or serotonin absorption inhibitors are used as modifiers of melotanin characteristics.
RU97113435/14A 1995-02-01 1996-01-29 Method for treating and preventing benzodiazepine group medicament addiction or insensitivity or toleration symptoms RU2182001C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US381.535 1995-02-01
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853.6 1995-06-06

Publications (2)

Publication Number Publication Date
RU97113435A true RU97113435A (en) 1999-06-27
RU2182001C2 RU2182001C2 (en) 2002-05-10

Family

ID=23505399

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97113435/14A RU2182001C2 (en) 1995-02-01 1996-01-29 Method for treating and preventing benzodiazepine group medicament addiction or insensitivity or toleration symptoms

Country Status (12)

Country Link
US (3) US6469044B1 (en)
EP (1) EP0724878B1 (en)
KR (1) KR100425045B1 (en)
AR (1) AR003921A1 (en)
DE (1) DE69512760T2 (en)
ES (1) ES2139842T3 (en)
IL (1) IL114296A (en)
LT (1) LT4339B (en)
RO (1) RO116771B1 (en)
RU (1) RU2182001C2 (en)
UA (1) UA63878C2 (en)
ZA (1) ZA96548B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176567A1 (en) 2012-05-24 2013-11-28 Общество С Ограниченной Ответственностью "Валента - Интеллект" Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
WO2014054965A1 (en) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
US6998112B2 (en) * 2003-03-18 2006-02-14 Arthur Zuckerman Sleep inducing toothpaste made with natural herbs and a natural hormone
RU2361583C2 (en) * 2003-10-03 2009-07-20 Вейлен Н.В. Application of compositions, capable to raise level of igf-1 in blood serum, at preparation of therapeutic composition for treatment of stages of various diseases, associated with depression of igf-1 level in serum of people and animals
EP1715742A4 (en) * 2004-02-20 2009-06-17 Lifescape Biosciences Inc Compositions and methods for sleep regulation
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
TR201808978T4 (en) 2011-02-11 2018-07-23 Zx Pharma Llc Multiparticulate 1-menthol formulations and related methods.
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
RS58325B1 (en) 2013-04-23 2019-03-29 Zx Pharma Llc ENTEROSOLVENTALLY SUBMITTED MULTI-PARTICULAR PROTEIN SUB-COAT PREPARATION
MX386987B (en) 2016-10-31 2025-03-19 Neurim Pharma 1991 MELATONIN MINI-TABLETS AND METHODS OF MANUFACTURING SAME.
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
AU601736B2 (en) 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
DK0518468T3 (en) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatonin-containing compositions
IT1251544B (en) 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176567A1 (en) 2012-05-24 2013-11-28 Общество С Ограниченной Ответственностью "Валента - Интеллект" Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
WO2014054965A1 (en) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders

Similar Documents

Publication Publication Date Title
RU97113435A (en) METHOD FOR TREATMENT OF DRUG ADDICTION, AND ALSO PATIENTS WITH DEPENDENCE SYMPTOMS, OR INDEPENDENCE, OR ADDICTION TO MEDICINES OF THE BENZODIAZEPINE GROUP
PT97552A (en) METHOD FOR PREPARING FORMS OF DOSAGE FOR THE ADMINISTRATION OF DRUGS FOR THE TREATMENT OF PARKISON'S DISEASE
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
KR930007441A (en) medicine
WO2000030446A1 (en) Dosage formulations for acetylcholinesterase inhibitors
NO890186L (en) PROCEDURE FOR THE PREPARATION OF A DELIVERY AND / OR DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES.
RU96102019A (en) The use of isovaleramide as a means of producing an anxiolytic effect and as a hypnotic and a pharmaceutical composition for this application
BR9607964A (en) Process of preparing a drug to treat inflammatory bowel disease
RO116771B1 (en) Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines
RU2000114174A (en) APPLICATION OF PHOSPHOLIPID COMPLEXES OF EXTRACTS FROM VITIS VINIFERA AS ANTIATHEROSCLEROTIC AGENTS
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
RU2002124141A (en) APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS
WO1996023496B1 (en) Use of melatonin for treating patients suffering from drug addiction
RU2067442C1 (en) Method for alleviating complicated abstinence syndrome
Nolen Tranylcypromine in depression resistant to cyclic antidepressions
EP0652760A1 (en) Therapeutic methods using caesium ions
EP0901376A1 (en) Malatonin in combination with analgesics
KR890007728A (en) Painkiller
Van Moffaert et al. A double-blind comparison of nefazodone and imipramine in the treatment of depressed patients.
KR910007528A (en) Use of Benzodiazepines and Phenylpyrylketone Derivatives
RU99112967A (en) METHOD FOR TREATMENT AND PREVENTION OF PIG DYSENTERY
SU351549A1 (en) Drug "Secufedrin" for the treatment of enuresis
Bohl et al. A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis
Kato et al. Melatonin treatment for rhythm disorder